Reply to: Can circulating CD34+ cells count be used for the prognosis of myelofibrosis? Probably yes, at least in patients treated with ruxolitinib.

REFERENCES 1 Zhang Y. Can circulating CD34+ cell count be used for the prognosis of myelofibrosis? Consequently, it would be important to evaluate the feasibility of including a CD34+ cells count in other standard prognostic stratification models as well (e.g., IPSS/DIPSS/DIPSS-plus for PMF and MYSEC-PM for SMF). Reply to: Can circulating CD34+ cells count be used for the prognosis of myelofibrosis?. [Extracted from the article]